Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era

To assess the efficacy of cytoreductive nephrectomy for Japanese patients with primary metastatic renal cell carcinoma in the cytokine and targeted therapy era.

[1]  T. Choueiri,et al.  Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. , 2014, European urology.

[2]  J. Brooks,et al.  Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era , 2014, International journal of cancer.

[3]  Juan P. Wisnivesky,et al.  Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis , 2013, World Journal of Urology.

[4]  L. Kiemeney,et al.  Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. , 2011, European journal of cancer.

[5]  P. Tamboli,et al.  Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  V. Margulis,et al.  Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? , 2010, Cancer.

[7]  Y. Tomita,et al.  Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. , 2010, European urology.

[8]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Patard,et al.  Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. , 2009, Urology.

[11]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[12]  C. Wood.  The role of cytoreductive nephrectomy in the management of metastatic renal cell carcinoma. , 2003, The Urologic clinics of North America.

[13]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[14]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[15]  T. Choueiri,et al.  The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. , 2011, The Journal of urology.

[16]  Dae-Ho Lee,et al.  The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. , 2011, The Journal of urology.